A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Prior treatment

• Patients with bacterial, viral, fungal, or parasitic infections recognized within 28 days prior to obtaining consent
• Patients with an infectious disease requiring hospitalization or IV administration of antimicrobial, antiviral, antifungal, or antiparasitic drugs within 24 weeks prior to obtaining consent

Other illness

• Current illness requiring treatment
• History of or current respiratory disease, heart disease, gastrointestinal disease, kidney disease, liver disease, psychiatric disease, autoimmune disease, or Cancer.
• History or of current drug allergy

Lab values

• Complications of active lupus nephritis(urinary column (granular column or red blood cell column), hematuria (\>5 red blood cells/high power field, excluding other causes such as stones or infection), proteinuria \>0.5 g/24 h, pyuria (\>5 white blood cells/high power field excluding infection)) or active central nervous lupus (delirium, psychiatric symptoms, seizures, etc.)

Other

• Patients with serious complications that are judged by the investigator or sub-investigator to affect the conduct and evaluation of the study.

• Voluntary written informed consent to participate in the study
• Japanese or non-Asian healthy men 18 to \< 50 years at the time of informed consent
• BMI 18.5 to \< 30.0 at screening
• Voluntary written informed consent to participate in the study
• Age 18 years to \< 75 years at the time of informed consent
• Weight over 40 kg and BMI 18.5 to \< 35.0 at screening
• Patients who meet any of the following criteria
  • Patients who meet the EULAR/ACR 2019 SLE classification criteria and have a diagnosis of SLE by screening
  • Patients with CLE diagnosed by skin biopsy